Jeremy C. Lowe

Partner

Jeremy Lowe’s practice focuses on the trial and appeal of intellectual property matters.  He is a member of the Intellectual Property and Biomedical Practice Groups.

Mr. Lowe has a degree in chemical engineering and has experience in complex patent litigation and counseling with a particular emphasis in pharmaceuticals and medical devices, including patent litigation arising under Section 505(j) of the Federal Food, Drug and Cosmetic Act.  Examples of recent or ongoing cases handled by Mr. Lowe include:

Eastman Kodak Co. v. Agfa-Gevaert N.V. and Agfa Corp., Civil Action No. 02-CV-6564 T-B (W.D. N.Y. 2002) (in May 2007, defended to verdict a five-year long patent infringement dispute between two major photographic film manufacturers involving seven patents and over a dozen product lines)

Mykrolis Corp. v. Pall Corp., Civil Action No. 03-CV-10392 GAO (D. Mass. 2003) (defended a filter manufacturer against a preliminary injunction request)

Entegris Corp. v. Pall Corp., Civil Action Nos. 06-10601 and 11494 GAO (D. Mass. 2006) (patent infringement dispute involving quick-connect manifolds utilized in the microchip manufacturing industry)

Entegris, Inc. v. Pall Corp., 2004, 1440; 2005, 1265 -1266; 2006, 1374 (Fed. Cir. 2006) (relates to C.A. No. 03-CV-10392) (upheld lower court’s denial of a preliminary injunction)

Elan Corp., PLC et al. v. Actavis South Atlantic LLC, Civil Action No. 07-679 (SLR) (patent infringement dispute involving pharmaceutical products)

Tyco Healthcare Group, LP et al. v. Mutual Pharmaceutical Co., Inc. et al., Civil Action No. 07-1299 (SRC) (defended a pharmaceutical manufacturer against a preliminary injunction request)

Warner Chilcott Laboratories Ireland Ltd. et al. v. Actavis Elizabeth LLC et al.  Civil Action No. 09-cv-469 (WJM) (MF) (patent infringement dispute involving pharmaceutical products)

Mr. Lowe is an experienced prosecutor and is registered to practice before the U.S. Patent and Trademark Office.  He has prosecuted numerous domestic and international patent applications for the National Institutes of Health and pharmaceutical manufacturers.  He has been involved in several proceedings before the Board of Patent Appeals and Interferences.  Examples of interferences handled by Mr. Lowe include:

Interference No. 104,782 (interested parties included Illinois Tool Works and Kimberly-Clark) (initiated and settled priority dispute involving the paper manufacturing and fabric assembly industries)

Interference No. 105,481 (interested parties included the National Institutes of Health, Medtronic and Boston Scientific) (initiated and settled priority dispute involving drug-coated stents)

Mr. Lowe was quoted in “Intellectual Property Rights in the M&A Process” in Financier Worldwide’s June 2009 edition, reporting on the complexities of the M&A process at the crossroads of intellectual property and antitrust.

Mr. Lowe was also quoted in “US Patent Reform Prospects Unclear; First-To-File Questioned” in Intellectual Property Watch’s May 19, 2009 article along with Professor Lemley and former USPTO Director Jon Dudas.  Mr. Lowe was quoted regarding the Patent Reform provisions for the permissive use of interlocutory appeals and other reform measures.

Mr. Lowe was featured in “IP Playbook Can Save Companies From ‘World of Hurt’” in IPLaw360’s June 4, 2008 issue discussing strategic intellectual property acquisition and enforcement strategies.

Mr. Lowe speaks extensively to both attorneys and business executives about patent portfolio and litigation strategies in an increasingly globally competitive environment.  For example, as part of a panel that included Professor John F. Duffy and other distinguished academics and professionals, he recently addressed the AIPLA at its 2009 Annual Meeting in Washington, D.C. about “Intellectual Property and Ethics – 2009 Annual Review.”

Throughout the United States he has spoken on these and other topics, including:

“Managing Infringement Exposure in the U.S.” (2005)

“Managing U.S. Patent Litigation Overseas” (2006)

“Sweeping Changes to U.S. Patent Law—How Your Company Can Navigate these Uncertain Times” (2006)

“Avoiding Compulsory Licenses in the Post-eBay Era” (2007)

“The Patent Playbook—How Corporate Counsel and Business Executives Can Work Together to Derive Profits from Your Global Patent Assets” (2008)

“The Impact of Recent Decisions on Pharmaceutical Patent Due Diligence” (2008)

“An Entrepreneurial Company’s Guide for Developing Profits from Patent Assets” (2009)

“Due Diligence in the Patent Evolution Era” (2009)

“Intellectual Property and Ethics – 2009 Annual Review” (2009)

Before joining the firm, Mr. Lowe was a partner of Leydig, Voit & Mayer, Ltd., and practiced out of that firm’s Chicago office.

Mr. Lowe is currently a voting member of AIPLA’s Patent Law Committee, which reviews proposed legislation and recommends legislative changes to the patent laws.

Bar & Court Admissions

• Connecticut
• Illinois
• New York
• U.S. Court of Appeals for the Federal Circuit
• U.S. District Court District of Connecticut
• U.S. District Court Northern District of Illinois
• U.S. Patent and Trademark Office

Education

• Washington University, St. Louis, Missouri, 1999 J.D.
• University of Missouri-Columbia, Columbia, Missouri, 1996 B.S. Chemical Engineering

Publications

• Raising Questions About Patent Deception, Connecticut Law Tribune, October 13, 2008
• Fed. Cir. Reins In Inequitable Conduct Doctrine, IPLaw360, September 9, 2008

Professional Activities

• Connecticut Intellectual Property Lawyers Association
• American Intellectual Property Lawyers Association, Patent Law Committee
• Illinois State Bar Association
• American Bar Association
• American Institute of Chemical Engineers
• Licensing Executives Society, Membership Committee
• Washington University School of Law Intellectual Property Law Advisory Board